Alternative Data for Biotechnology and Pharmaceutical Financial Modeling and Time Series Analysis
BUILD AND BACKTEST YOUR FINANCIAL MODELS WITH ANNOTATED DRUG PATENTS, SALES, AND LITIGATION Apply your financial models to our […]
Insights
Insights
Reviving a Discontinued Drug
When drugs are taken off the market because of concerns about their safety, it makes headlines. To access DrugPatentWatch’s list
Finding and Evaluating Branded and Generic Market Entry Opportunities
Here’s a copy of the recent talk on Finding and Evaluating Branded and Generic Market Entry Opportunities. It’s based on
Finding and Evaluating Branded and Generic Market Entry Opportunities Read Post »
Drug Prices and Generic Competition
You would be surprised to find out just how many questions are answered by the analysis of the relationship that
Valuation of Pharma Companies: 5 Key Considerations
Introduction Valuing pharmaceutical companies is a complex yet crucial task for investors, analysts, and stakeholders. The unique nature of the
Valuation of Pharma Companies: 5 Key Considerations Read Post »
Opportunities for Generic Drug Development
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about
Finding hidden treasures in old drugs: the challenges and importance of licensing generics
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J.
How Big Data Is Remodelling The Drug Industry
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of
First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
